The Europe Thyroid Ablation Devices Market would witness market growth of 12.6% CAGR during the forecast period (2022-2028).
Procedures for thyroid ablation are effective because they potentially carry fewer risks, are less invasive, preserve more thyroid tissue, and aid patients in maintaining normal thyroid function. Radiation exposure is known to raise the risk of developing thyroid cancer. The International Agency for Research on Cancer (IARC) has discovered that having thyroid cancer increases the risk of being overweight or obese. Follicular thyroid carcinoma is more common in areas with poor iodine consumption.
However, iodine-rich food may increase the likelihood of papillary thyroid cancer. More ablation operations are being performed as thyroid cancer incidence rises. In addition, thyroid nodules are on the rise, and they are one of the more common endocrine system illnesses. Therefore, the development of the thyroid ablation devices market is also predicted to be boosted by the introduction of advanced ablation techniques.
Differentiated thyroid cancer (DTC) has been steadily increasing over the past few decades in Europe, with estimates for male and female populations of 3 and 9 cases per 100,000 person-years, respectively. Even though there are epidemiological variations between nations, papillary thyroid cancer (PTC) accounts for 80–85% of instances, follicular cancer for roughly 5%–10%, and medullary and anaplastic cancer for the remainder. Since the mortality rate for this disease is low, most DTCs are not considered to be aggressive tumors. This is further propelling the growth of the thyroid ablation devices market in the coming years.
The Germany market dominated the Europe Thyroid Ablation Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $19,172.8 Thousands by 2028. The UK market is anticipated to grow at a CAGR of 11.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 13.4% during (2022 - 2028).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Specialty Centers and Others. Based on Type, the market is segmented into Radiofrequency Ablation, Microwave Ablation and Others. Based on Application, the market is segmented into Thyroid Cancer and Thyroid Nodules. Based on Product, the market is segmented into Thermal-based Devices and Non-thermal-based Devices. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Thyroid Ablation Devices Market will Hit $289.9 Million by 2028, at a CAGR of 13%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Boston Scientific Corporation, Integra LifeSciences Holdings Corporation, Johnson & Johnson, Theraclion SA, Olympus Corporation, Terumo Corporation, BVM Medical Limited, MedWaves, Inc., and STARmed Co. Ltd.
By End-use
By Type
By Application
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 